Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors

Multifunctional rational drug design of protein tyrosine kinases inhibitors allows a potent drug to be utilized to treat more than one disease for greater patient benefits. Many protein tyrosine kinases (PTK), including Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), have been identif...

Full description

Saved in:
Bibliographic Details
Published inCurrent drug targets Vol. 7; no. 3; p. 327
Main Authors Vassilev, Alexei O, Tibbles, Heather E, DuMez, Darin, Venkatachalam, Taracad K, Uckun, Fatih M
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.03.2006
Subjects
Agammaglobulinaemia Tyrosine Kinase
Animals
Autoimmune Diseases - drug therapy
Diabetes Mellitus, Type 1 - drug therapy
Drug Delivery Systems
Drug Design
Enzyme Inhibitors - pharmacology
Humans
Janus Kinase 3
Neoplasms - complications
Neoplasms - drug therapy
Organ Transplantation - physiology
Protein-Tyrosine Kinases - antagonists & inhibitors
Online AccessGet more information

Cover

More Information
Summary:Multifunctional rational drug design of protein tyrosine kinases inhibitors allows a potent drug to be utilized to treat more than one disease for greater patient benefits. Many protein tyrosine kinases (PTK), including Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), have been identified as potential drug targets to treat diverse diseases including cancer and disorders of the immune system. Here we review advances in JAK3 and BTK inhibitors and describe the therapeutic potential of these potent agents in the clinical setting.
ISSN:1389-4501
DOI:10.2174/138945006776054997